AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29252011 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation (PE) condition
Number of subjects: 69
Study 26695436 — intervention group
Group type: EXPERIMENTAL
Intervention: NB‐UVB therapy plus intradermal injection of PRP every 2 weeks for 4 months
Number of subjects: 60
Study 26695436 — intervention group
Group type: COMPARATOR
Intervention: NB‐UVB alone (control side)
Number of subjects: 60
Study 24648359 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness education program (8 sessions of 2.5 hours per week plus a 1-day session of 8 hours)
Number of subjects: 68
Study 24648359 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 22187107 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint attention intervention
Number of subjects: 0
Study 22187107 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbolic play intervention
Number of subjects: 0
Study 22187107 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 19763634 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular Metal (TM)
Number of subjects: 80
Study 19763634 — intervention group
Group type: COMPARATOR
Intervention: Smith-Robinson (SR) with autograft
Number of subjects: 80
Study 18846799 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PVP) performed by injecting polymethylacrylate in the diseased vertebral body.
Number of subjects: 24
Study 15946597 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Cloril tablet (Test formulation)
Number of subjects: 0
Study 15946597 — intervention group
Group type: COMPARATOR
Intervention: 100 mg Clozaril tablet (Reference formulation)
Number of subjects: 0
Study 11942772 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil (900 mg)
Number of subjects: 21
Study 11942772 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg)
Number of subjects: 21
Study 11316966 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine (4 mg)
Number of subjects: 52
Study 11316966 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine (10 mg)
Number of subjects: 52
Study 11316966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 10322842 — intervention group
Group type: EXPERIMENTAL
Intervention: Baoyuan Qiangshen (BQ) II tablet
Number of subjects: 40
Study 10322842 — intervention group
Group type: COMPARATOR
Intervention: Essential amino acid added capoten
Number of subjects: 40
Study 8295088 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% ferric oxalate in 0.9% saline
Number of subjects: 25
Study 8295088 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 25
Study 3098129 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% sodium cromoglycate (SCG) in an oil-in-water cream
Number of subjects: 40
Study 3098129 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo cream
Number of subjects: 40
Study 29098469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary arachidonic acid (ARA) levels from 1 to 6% of total fatty acids
Number of subjects: 0
Study 29098469 — intervention group
Group type: COMPARATOR
Intervention: Negative control diet with total fish oil replacement and defatted fish meal containing 0.1-g ARA g‐1 diet
Number of subjects: 0
Study 29098469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary ARA levels
Number of subjects: 0
Study 28933745 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (160 mg/day for six weeks)
Number of subjects: 18
Study 28933745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 25816377 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental consultation room design (pedestal table replacing examination table)
Number of subjects: 0
Study 25816377 — intervention group
Group type: COMPARATOR
Intervention: Traditional consultation room design
Number of subjects: 0
Study 24244261 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide plus cetuximab combination therapy
Number of subjects: 51
Study 24244261 — intervention group
Group type: COMPARATOR
Intervention: lenalidomide 25 mg/day monotherapy
Number of subjects: 51
Study 21146636 — intervention group
Group type: EXPERIMENTAL
Intervention: Phased individually-tailored 10-week walking program
Number of subjects: 154
Study 21146636 — intervention group
Group type: COMPARATOR
Intervention: Maintain usual activity (Control)
Number of subjects: 154
Study 18308007 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased right ventricular fractional area change (RVFAC)
Number of subjects: 605
Study 16556245 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) increase
Number of subjects: 21337
Study 16556245 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) increase
Number of subjects: 21337
Study 16556245 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse Pressure increase
Number of subjects: 21337
Study 16556245 — intervention group
Group type: COMPARATOR
Intervention: Comparison of BP between migraine patients and controls
Number of subjects: 21337
Study 12656878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral surgeon
Number of subjects: 30
Study 12656878 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical assistant
Number of subjects: 30
Study 12656878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthodontist
Number of subjects: 30
Study 12656878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral surgeon (total time including unscheduled visits)
Number of subjects: 30
Study 12656878 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical assistant (total time including unscheduled visits)
Number of subjects: 30
Study 12656878 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthodontist (total time including unscheduled visits)
Number of subjects: 30
Study 12656878 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled visits
Number of subjects: 30
Study 14733634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDCP) 100 mg/m2
Number of subjects: 83
Study 14733634 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose cisplatin (MDCP) 50 mg/m2 combined with ifosfamide (3 g/m2) and mitomycin (6 mg/m2)
Number of subjects: 83
Study 14733634 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cisplatin (HDCP)
Number of subjects: 83
Study 14733634 — intervention group
Group type: COMPARATOR
Intervention: Moderate-dose cisplatin (MDCP)
Number of subjects: 83
Study 8960474 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Number of subjects: 546
Study 8960474 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cisplatin (100 mg per square meter) plus intravenous cyclophosphamide (600 mg per square meter)
Number of subjects: 546
Study 1285270 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 47
Study 1285270 — intervention group
Group type: COMPARATOR
Intervention: Baseline plasma levels of MHPG and HVA
Number of subjects: 47
Study 1285270 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment using Hamilton depression rating scale and BPRS
Number of subjects: 47
Study 1285270 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma catabolites MHPG, 5‐HIAA, HVA
Number of subjects: 47
Study 29630752 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic rapid-inflation (RI) system
Number of subjects: 18
Study 29630752 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual handheld pump and sphygmomanometer (HS) system
Number of subjects: 18
Study 29630752 — intervention group
Group type: COMPARATOR
Intervention: Automatic personalized tourniquet (PT) system
Number of subjects: 18
Study 27558507 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban with foot pump
Number of subjects: 124
Study 27558507 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban without foot pump
Number of subjects: 124
Study 27558507 — intervention group
Group type: COMPARATOR
Intervention: Fondaparinux
Number of subjects: 124
Study 25609549 — intervention group
Group type: EXPERIMENTAL
Intervention: Raisins
Number of subjects: 51
Study 25609549 — intervention group
Group type: COMPARATOR
Intervention: Alternative processed snacks
Number of subjects: 51
Study 23632669 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar hemiarthroplasty (HA)
Number of subjects: 96
Study 23632669 — intervention group
Group type: COMPARATOR
Intervention: Novel total hip replacement (PCU-THR)
Number of subjects: 96
Study 23632669 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcome assessed with the Harris hip score (HHS)
Number of subjects: 96
Study 20628363 — intervention group
Group type: EXPERIMENTAL
Intervention: Fujinon intelligent chromoendoscopy (FICE)
Number of subjects: 1318
Study 20628363 — intervention group
Group type: COMPARATOR
Intervention: White light imaging
Number of subjects: 1318
Study 20628363 — intervention group
Group type: EXPERIMENTAL
Intervention: FICE
Number of subjects: 1318
Study 18245509 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions
Number of subjects: 30
Study 16643193 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training at 100 degrees (longer muscle length: LT)
Number of subjects: 9
Study 16643193 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric training at 50 degrees (shorter muscle length: ST)
Number of subjects: 9
Study 12600848 — intervention group
Group type: COMPARATOR
Intervention: Whole-grain breakfast cereal intake (>= 1 serving/day)
Number of subjects: 86190
Study 12600848 — intervention group
Group type: COMPARATOR
Intervention: Refined-grain breakfast cereal intake
Number of subjects: 86190
Study 12600848 — intervention group
Group type: COMPARATOR
Intervention: Total breakfast cereal intake
Number of subjects: 86190
Study 11020403 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy
Number of subjects: 117
Study 11020403 — intervention group
Group type: COMPARATOR
Intervention: Ahmed implant
Number of subjects: 117
Study 11020403 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy and Ahmed implant
Number of subjects: 117
Study 8795090 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine (20 ng/kg per min for 30 min)
Number of subjects: 8
Study 8795090 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine (40 ng/kg per min for 30 min)
Number of subjects: 8
Study 1290733 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-volume spacers (Nebuhaler, Volumatic)
Number of subjects: 0
Study 1290733 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath actuated dry-power inhalers (Rotahaler, Diskhaler, Turbohaler)
Number of subjects: 0
Study 6695826 — intervention group
Group type: EXPERIMENTAL
Intervention: Criticare HN
Number of subjects: 12
Study 6695826 — intervention group
Group type: COMPARATOR
Intervention: Vivonex HN
Number of subjects: 12
Study 31744345 — intervention group
Group type: EXPERIMENTAL
Intervention: CML-enriched maternal milk formulation (8 mg GA per day)
Number of subjects: 1500
Study 31744345 — intervention group
Group type: COMPARATOR
Intervention: Control maternal milk formulation (4 mg GA per day)
Number of subjects: 1500
Study 31744345 — intervention group
Group type: COMPARATOR
Intervention: No maternal milk supplementation with standard obstetric care
Number of subjects: 1500
Study 30992195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg)
Number of subjects: 461
Study 30992195 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (10 mg) and Saxagliptin (2.5 mg)
Number of subjects: 461
Study 30992195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study 27896805 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention addressing expressed emotion
Number of subjects: 0
Study 27896805 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-family home sessions
Number of subjects: 0
Study 28101379 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 18 months in daily practice
Number of subjects: 19
Study 28101379 — intervention group
Group type: COMPARATOR
Intervention: Metformin treatment for 18 months in RCT
Number of subjects: 19
Study 24699854 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-dairy protein blend
Number of subjects: 16
Study 24699854 — intervention group
Group type: COMPARATOR
Intervention: Whey protein
Number of subjects: 16
Study 22580119 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-sparing helical tomotherapy (HT)
Number of subjects: 50
Study 22580119 — intervention group
Group type: COMPARATOR
Intervention: 3D-conformal radiotherapy (3D-CRT)
Number of subjects: 50
Study 20865876 — intervention group
Group type: COMPARATOR
Intervention: 4 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Number of subjects: 67
Study 20865876 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg x kg(‐1) ketamine, 0.5 mg x kg(‐1) midazolam, 0.02 mg x kg(‐1) atropine
Number of subjects: 67
Study 16822792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrapure dialysate (UPD)
Number of subjects: 78
Study 16822792 — intervention group
Group type: COMPARATOR
Intervention: Conventional dialysate (CD)
Number of subjects: 78
Study 15144492 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual preference procedures for 6- and 7-month-olds
Number of subjects: 0
Study 15144492 — intervention group
Group type: COMPARATOR
Intervention: Visual preference procedures for 3- to 4-month-olds
Number of subjects: 0
Study 11061280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (20 mg daily for 4 weeks, then 10 mg daily for 1 year, followed by gradual withdrawal over 16 weeks)
Number of subjects: 138
Study 11061280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 11061280 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 138
Study 9068508 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 173
Study 9068508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 8375267 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine NPH insulin
Number of subjects: 29
Study 8375267 — intervention group
Group type: EXPERIMENTAL
Intervention: Human NPH insulin
Number of subjects: 29
Study 3503120 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyelid closure (ELC)
Number of subjects: 8
Study 3503120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasolacrimal occlusion (NLO)
Number of subjects: 8
Study 3503120 — intervention group
Group type: COMPARATOR
Intervention: Normal blinking (Control)
Number of subjects: 8
Study 29804485 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 30 sunblock stick
Number of subjects: 20
Study 29804485 — intervention group
Group type: COMPARATOR
Intervention: No sunblock protection
Number of subjects: 20
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at single visits (13, 26, 39, or 52 weeks)
Number of subjects: 144
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at consecutive visits (13 and 26, 26 and 39, or 39 and 52 weeks)
Number of subjects: 144
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at single visits
Number of subjects: 144
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria at consecutive visits
Number of subjects: 144
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission according to ACR/EULAR criteria
Number of subjects: 144
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Single DAS remission
Number of subjects: 144
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained remission periods
Number of subjects: 144
Study 27696732 — intervention group
Group type: EXPERIMENTAL
Intervention: (Sustained) remission
Number of subjects: 144
Study 26383996 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 1185
Study 26383996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 1185
Study 26383996 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment change candidates at week 12
Number of subjects: 1185
Study 26383996 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment change candidates at week 24
Number of subjects: 1185
Study 23394146 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind placebo-controlled food challenge (DBPCFC)
Number of subjects: 116
Study 21252061 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and gemcitabine (CG)
Number of subjects: 181
Study 21252061 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 181
Study 19583678 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous for Arg92 allele
Number of subjects: 52
Study 19583678 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 7 survivors
Number of subjects: 52
Study 17456913 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid gel
Number of subjects: 60
Study 17456913 — intervention group
Group type: COMPARATOR
Intervention: Vehicle gel (placebo)
Number of subjects: 60
Study 15868618 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant relaxin treatment
Number of subjects: 239
Study 15868618 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire Disability Index (HAQ‐DI)
Number of subjects: 239
Study 15868618 — intervention group
Group type: EXPERIMENTAL
Intervention: SF‐36
Number of subjects: 239
Study 15868618 — intervention group
Group type: EXPERIMENTAL
Intervention: HAQ‐DI
Number of subjects: 239
Study 12537345 — intervention group
Group type: EXPERIMENTAL
Intervention: GCB+D (Gluma Comfort Bond + Desensitizer)
Number of subjects: 119
Study 12537345 — intervention group
Group type: COMPARATOR
Intervention: GCB (Gluma Comfort Bond)
Number of subjects: 119
Study 12537345 — intervention group
Group type: EXPERIMENTAL
Intervention: GCB (Gluma Comfort Bond) with rescue treatment using Gluma Desensitizer
Number of subjects: 119
Study 9708388 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrasheath injection
Number of subjects: 95
Study 9708388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed sheath and subcutaneous injection
Number of subjects: 95
Study 9708388 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous injection
Number of subjects: 95
Study 8570768 — intervention group
Group type: EXPERIMENTAL
Intervention: meta-chlorophenylpiperazine (m-CPP)
Number of subjects: 67
Study 8570768 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 67
Study 8570768 — intervention group
Group type: EXPERIMENTAL
Intervention: m-CPP
Number of subjects: 67
Study 2223415 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 81
Study 2223415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 81
Study 357754 — intervention group
Group type: EXPERIMENTAL
Intervention: brompheniramine maleate and phenylpropanolamine hydrochloride (Lunerin mite)
Number of subjects: 44
Study 31179500 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) <110 mmHg
Number of subjects: 3598
Study 31179500 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic Blood Pressure (SBP) 130 - <140 mmHg
Number of subjects: 3598
Study 31179500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) 60 - <70 mmHg
Number of subjects: 3598
Study 31179500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic Blood Pressure (DBP) 80 - <90 mmHg
Number of subjects: 3598
Study 28730950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lying flat (0°) head positioning
Number of subjects: 140
Study 28730950 — intervention group
Group type: COMPARATOR
Intervention: Sitting up (≥30°) head positioning
Number of subjects: 140
Study 25703461 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp tube voltage with iDose algorithm (group B)
Number of subjects: 98
Study 25703461 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 kVp tube voltage with non-tagged algorithm (group B)
Number of subjects: 98
Study 25703461 — intervention group
Group type: COMPARATOR
Intervention: 120 kVp tube voltage with standard filtered back projection (FBP) algorithm (group A)
Number of subjects: 98
Study 23213072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for six months
Number of subjects: 75
Study 23213072 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75
Study 23213072 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention for six months (among those reaching 80% of intervention goal)
Number of subjects: 75
Study 20926981 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume analysis in addition to pulmonary artery catheter parameters
Number of subjects: 0
Study 20926981 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary artery catheter alone
Number of subjects: 0
Study 18683898 — intervention group
Group type: COMPARATOR
Intervention: Binge eating disorder pharmacotherapy trials (specific interventions not detailed in the abstract)
Number of subjects: 2685
Study 18683898 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusionary psychotropic medication
Number of subjects: 2685
Study 18683898 — intervention group
Group type: EXPERIMENTAL
Intervention: BED criteria
Number of subjects: 2685
Study 18683898 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and weight range
Number of subjects: 2685
Study 18683898 — intervention group
Group type: EXPERIMENTAL
Intervention: Prohibited medical or psychiatric disorders
Number of subjects: 2685
Study 18683898 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss programmes
Number of subjects: 2685
Study 16423672 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior myocardial infarction (MI)
Number of subjects: 16
Study 16423672 — intervention group
Group type: COMPARATOR
Intervention: Anterior myocardial infarction (MI)
Number of subjects: 16
Study 15627931 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 3 days
Number of subjects: 286
Study 15627931 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 4 days
Number of subjects: 286
Study 15627931 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 5 days
Number of subjects: 286
Study 15627931 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpebral hygiene solution used for 6 days
Number of subjects: 286